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Abstract Clostridium difficile infection (CDI) is associated
with high mortality. Reducing incidence is a priority for pa-
tients, clinicians, the National Health Service (NHS) and Pub-
lic Health England alike. In June 2012, fidaxomicin (FDX)
was launched for the treatment of adults with CDI. The objec-
tive of this evaluation was to collect robust real-world data to
understand the effectiveness of FDX in routine practice. In
seven hospitals introducing FDX between July 2012 and July
2013, data were collected retrospectively from medical re-
cords on CDI episodes occurring 12 months before/after the
introduction of FDX. All hospitalised patients aged ≥18 years
with primary CDI (diarrhoea with presence of toxin A/B with-
out a previous CDI in the previous 3 months) were included.
Recurrence was defined as in-patient diarrhoea re-emergence
requiring treatment any time within 3 months after the first
episode. Each hospital had a different protocol for the use of
FDX. In hospitals A and B, where FDX was used first line for
all primary and recurrent episodes, the recurrence rate reduced
from 10.6 % to 3.1 % and from 16.3 % to 3.1 %, with a
significant difference in 28-day mortality from 18.2 % to
3.1 % (p<0.05) and 17.3 % to 6.3 % (p<0.05) for hospitals
A and B, respectively. In hospitals using FDX in selected
patients only, the changes in recurrence rates and mortality
were less marked. The pattern of adoption of FDX appears
to affect its impact on CDI outcome, with maximum reduction
in recurrence and all-cause mortality where it is used as first-
line treatment.
Introduction
Clostridium difficile infection (CDI) is a major public health
concern [1] and is associated with prolonged hospital stay [2,
3], hospital readmissions [4, 5] and increased mortality [6–8].
Recurrence of disease is a significant problem, with 20–30 %
of patients experiencing a recurrent episode following initial
resolution [9, 10]. The European Society of Clinical Microbi-
ology and Infectious Diseases (ESCMID) guidelines recog-
nise that the high recurrence rate is among the most important
problems posed by CDI [11]. In 2012, fidaxomicin (FDX)
became available in the UK for the treatment of CDI. Two
double-blind, randomised controlled trials (RCTs) showed
non-inferiority of FDX compared to vancomycin with respect
to initial CDI cure rates, and significantly lower recurrence
rates in patients treated with FDX [12, 13]. Data on the real-
world use of FDX outside of a clinical trial setting are lacking.
We report a series of local service evaluations conducted to
evaluate the impact of FDX introduction on service delivery
and CDI management in real-world conditions. Although
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conducted primarily to inform local decision-making, the re-
sults of the evaluations reported here detail differences in the
experiences of routine FDXuse in the English National Health
Service (NHS).
Materials and methods
A series of local service evaluations was conducted between
December 2013 and October 2014 in collaboration with micro-
biologists, infection control clinicians and pharmacists in seven
NHS hospitals in England, each offering a range of services,
including: secondary, tertiary, acute, long-stay, elective and
non-elective care. The primary objective of each evaluation
was to describe CDI recurrence rates occurring in the year before
(pre-) and after (post-) local introduction of FDX. Secondary
objectives included describing: time to clinical cure of CDI; 28-
day and 3-month all-cause mortality; CDI-related treatment path-
ways (including times from symptom onset to stool sampling,
diagnosis and symptom resolution) and resource use [hospital
length of stay (LOS), intensive care unit (ICU) admission rate
and LOS, duration of treatment, readmission rate and LOS for
both primary and recurrent episodes] in the year before and after
FDX introduction; and characteristics of patients receiving FDX.
Hospitals were invited to conduct an evaluation based on
interest in describing the impact of local FDX introduction
and the availability of at least 20 cases of CDI per year to
allow the generation of meaningful results locally. All
hospitals conducting an evaluation commenced FDX use be-
tween July 2012 and July 2013.
Service evaluations are exempt from ethical review and
patient consent in the UK [14]. Each hospital approved the
evaluation protocol and release of fully anonymised patient
data to pH Associates Ltd, a research consultancy company,
for analysis.
Each evaluation was conducted according to a common
protocol. Primary CDI was defined as diarrhoea with >3 con-
secutive unformed bowel movements and presence of C.
difficile toxin A/B in stool (see Table 1 for the testing
protocols). Two different definitions of CDI recurrence were
used to accommodate local differences in repeatingC. difficile
toxin testing within 28 days of the primary infection. In hos-
pitals A, C and G, policy was to define recurrence as symp-
tomatic (i.e. reappearance of diarrhoea to an extent, judged by
the frequency of passed unformed stools, that was greater than
the frequency noted on the last day of medication) with treat-
ment for CDI and toxin confirmed. In hospitals B, D, E and F,
policy was to assume recurrence if patients were symptomatic
and given treatment for CDI, without a requirement for toxin
testing. CDI was considered to be community-acquired if the
symptoms and/or sample for toxin testing were documented
within 48 h of hospital admission.
Recurrences presenting to the same hospital within 3
months of the primary CDI episode (first toxin-positive stool
sample) were recorded for the evaluation. Clinical cure was
defined as three or fewer unformed stools on two consecutive
Table 1 Clostridium difficile toxin testing policies and C. difficile infection (CDI) severity criteria
Hospital C. difficile toxin testing policy CDI severity criteria
A Two-step testing method: 1. glutamate dehydrogenase
(GDH) enzyme immunoassay (EIA); 2. C. difficile toxin EIA
According to the ESCMID definitions
B Two-step testing method: 1. GDH EIA; 2. C. difficile toxin EIA Severity parameters not collected for this evaluation
C Two-step testing method: 1. GDH EIA; 2. C. difficile cytotoxin assay Life-threatening: any of: hypotension (not responsive
to fluid challenge), partial or complete ileus or toxic
megacolon
Severe: any of: raised WCC >15×109/L., acute kidney
injury (e.g. >50 % rise in serum creatinine above baseline),
temperature of >38.5 ° C, evidence of severe colitis
(e.g. guarding, abdominal tenderness
Non-severe: diarrhoea without features of severe
or life-threatening infection
D Two-step testing method: 1. GDH EIA; 2. C. difficile toxin EIA According to PHE guidelines
E Three-step testing method: 1. screen with GDH EIA;
2. all GDH-positives are then tested for C .difficile toxin EIA;
3. if GDH-positive and toxin-negative, PCR testing
According to PHE guidelines
F Two-step testing method: 1. GDH EIA; 2. C. difficile
toxin EIA
GDH-positive, toxin-negative has another stool
sample tested at least 24 h later
According to PHE guidelines
G Three-step testing method: 1. screen with GDH EIA;
2. all GDH-positives are tested for C. difficile toxin EIA,
3. if GDH-positive and toxin-negative, PCR testing
According to PHE guidelines
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days following treatment. The date of diarrhoea resolution
was noted as recorded in clinical records; if this was unavail-
able, the date diarrhoea was last documented or the stop date
of CDImedication in the clinical record was noted. Severity of
CDI could not be defined objectively by retrospective review
and was recorded as documented in the clinical record.
Each evaluation included two 12-month retrospective ob-
servation periods for primary CDI episodes, one before and
one following local introduction of FDX. To ensure identifi-
cation of all recurrences within 3 months of a primary episode,
an additional 3-month observation period was included at the
end of each observation period, for the collection of recur-
rence data only (Fig. 1). Similarly, microbiology records for
the previous 3 months were checked for all CDI infections to
verify a primary rather than recurrent episode.
All patients with a positive toxin A/B test for C. difficile
within the evaluation period (pre- or post-FDX) were identified
frommicrobiology department records. Patients aged <18 years
were excluded, as were any cases that were diagnosed and
managed in a community setting without hospital admission.
The full evaluation data were obtained for all episodes in
the pre/post periods in all hospitals except hospital C. In this
hospital, all episodes were included in the recurrence rate end-
point (Table 4, row 1) but the full dataset was collected in only
a sample of patients in order to manage numbers (all other
tables). The sample was taken by selecting the first seven
episodes per month during the pre period and all electronically
available episodes in the post period, both methods generating
a random sample. Data were collected retrospectively from
patients’ hospital records, including paper notes and electronic
databases as appropriate in each hospital, using a standard data
extraction process. Data were fully anonymised for analysis.
The evaluation relied on data recorded routinely for patients’
clinical care. Analyses were conducted using the available
data, with the number of patients included in each analysis
stated where data were missing. Patients who died whilst in-
patients were excluded from LOS calculations.
FDX was adopted for different uses in each hospital, with
some using the agent first line in all patients (primary and
recurrent CDI), others only for CDI recurrence and others only
in selected patients (Table 2). In order to appreciate the re-
sponse to different patterns of use, the results of each evalua-
tion are presented separately, grouped according to the local
policy for the use of FDX.
Values for each measure were tabulated and examined vi-
sually for possible differences between treatments (pre- and
post-FDX) within each hospital. Differences between percent-
ages or rates were tested for statistical significance using the
Chi-squared (χ2) test, except when the total number of obser-
vations was too small and Fisher’s exact test was used. Con-
tinuous variables were compared using the unpaired t-test or
Mann–Whitney U-test, depending on data distributions and
homogeneity of the variance.
Results
The FDX prescribing policy at each hospital is shown in
Table 2. Following the introduction of FDX, hospitals A and
B used FDX for all patients and hospital D used FDX first line
in the single CDI recurrence but not for most primary CDI
episodes. Hospitals C, E, F and G used FDX first line only in
selected patients (primary and recurrent CDI).
The patient characteristics are shown in Table 3. The median
age at primary and recurrent CDI ranged from 70 to 81 years
and 43.5 to 84.5 years, respectively. Where severity was docu-
mented, the proportion of patients with primary CDI document-
ed as severe/complicated ranged from 7.4 % to 72.2 %. Where
documented, prior antibiotic use (within 3months) ranged from
74.1 % to 98.1 % and proton pump inhibitor use concurrent
Fig. 1 Service evaluation design
showing two retrospective
observation periods, before (pre)
and after (post) introduction of
fidaxomicin (FDX)
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with symptom onset from 0 % to 78.3 %. The proportion of
patients hospitalised for ≥7 days before CDI ranged from
31.5 % to 58.9 % and the proportion with a prior stay in the
ICU during the current hospital admission ranged from 0 % to
12.1 %. The proportion of community-acquired primary CDI
ranged from 18.6 % to 44.6 %.
Table 4 shows the clinical outcomes at each hospital in the
pre- and post-FDX periods. The recurrence rate from primary
episodes of CDI significantly reduced in the post-FDX period
in hospital B by 81.0 % (p=0.01, see Fig. 2). Hospitals A, D,
E and F had smaller, non-significant, relative reductions in
recurrence rates and hospitals C and G had small non-
significant relative increases in recurrence rates.
Also shown in Table 4, the median time from diagnosis of
primary CDI to diarrhoea resolution in the post-FDX period
increased significantly in hospitals A and C, but remained sim-
ilar in other hospitals. The median LOS for the primary CDI
increased in the post-FDX period in hospital A (p=0.01) and
non-significantly in hospital B (p=0.06), but remained similar
in other hospitals. The readmission rate within 30 days of dis-
charge after the primary CDI reduced in the post-FDX period in
hospital A (p<0.05). There were no significant changes in any
other hospital. The median LOS for recurrent CDI episodes
showed no significant difference in any hospital between the
pre-/post-FDX periods, although the number of recurrences was
small. Rates of readmission within 30 days following recur-
rences showed a non-significant reduction in the post-FDX pe-
riod in all five hospitals providing this data, although the num-
bers were small. All-cause mortality within 28 days of primary
episodes reduced significantly in the post-FDX period in hos-
pitals A, B and D, reduced non-significantly in hospitals C, E
and G, and non-significantly increased in hospital F (Table 4).
No adverse events attributed to FDX had been documented
in the medical records of any of the patients included in these
evaluations.
Discussion
This series of local service evaluations was conducted primar-
ily for local use but, considered together, the results provide
some useful insights on the real-world impact of different
FDX adoption strategies.
As expected, patients with CDI were predominantly elderly,
with a median age of at least 70 years across the hospitals. The
severity of primary CDI was not recorded for all patients in
some hospitals, providing an incomplete picture. The wide var-
iation between hospitals in the proportion of patients with
severe/complicated CDI also suggests that severity may not
be assessed according to the same criteria in different hospitals.
Variation in the proportion of patients with community-
acquired CDI between hospitals could be partly a reflection of
local outbreaks. It would be interesting to understand the impact
of FDX on different ribotypes of C. difficile in the real world;
however, this information was not and is not routinely docu-
mented in the normal practice of these hospitals; it may be the
subject for potential further study with a prospective design.
Pre-FDX recurrence rates varied between hospitals (5.4–
21.1 %) but were generally lower than commonly quoted ex-
pected recurrence rates of 20–30 % [15, 16]. It is difficult to
compare the results of RCTs with real-world evaluations
(RWE) because RCTs generally include highly selected patients
in a controlled environment, with strict monitoring, while RWE
do not; hence, the difference is most likely to be due to less
rigorous surveillance for returning symptoms, and different test-
ing and reporting requirements for recurrences outside an RCT.
The greatest reduction in relative recurrence rates (>70 %)
was observed in the two hospitals that used FDX as first line in
all patients with CDI. RCTs showed that FDX reduced recur-
rence rates compared with vancomycin [12, 13] and, there-
fore, the reduced recurrence in hospitals A and B are consis-
tent with expectations, since all patients were treated with
FDX in the post-FDX period. In contrast, the hospitals using
FDX more selectively (e.g. only in the elderly or those with
severe CDI) observed more modest reductions in relative re-
currence rates. Conversely, two hospitals where FDX was
used most selectively (chiefly for recurrences only) observed
a non-significant increase in recurrence rates.
These data suggest that FDX is most effective when used in
all patients with CDI, with no clear indication of patient sub-
groups most likely to benefit. However, the recurrence rates in
all hospitals, irrespective of the pattern of adoption of FDX
(3.1–12.5 %), were lower than those seen in the pivotal clinical
trials (12.7–15.4 %) [12, 13], despite a shorter window for
recording recurrence in the trials (30 days) compared to the
service evaluations (3 months). This may be explained by the
implementation of other infection control measures in the in-
tervening period or changing patterns of ribotypes causing dis-
ease and/or the follow-up for recurrence in these evaluations
only during the hospital admission and any readmissions,
missing CDI recurrences diagnosed in the community.
The time to resolution of diarrhoea was not positively affect-
ed by the introduction of FDX in most hospitals and, in fact,
there was a statistically significant increase from 7.5 to 13.0 days
in hospital A and from 9 to 10 days in hospital C. However, the
resolution of symptoms was not well documented in patients’
clinical notes, with proxy measures for symptom resolution col-
lected in the absence of definitive documentation, making it
difficult to infer the impact of FDX on symptom resolution.
The LOS for primary and recurrent episodes of CDI was not
significantly affected by the introduction of FDX in any hospi-
tals, and, in fact, increased in all except one hospital. The factors
affecting the LOS remain unclear but may reflect the well-
recognised challenge of discharging patients (particularly the
elderly) from hospital [17–19]. The increase in LOS was most
marked in hospitals A and B. These hospitals also demonstrated
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a significant reduction in 28-day mortality in the post-FDX
period. Whilst purely speculative, it is possible that the in-
creased LOSmay be related to improved survival, with patients
who might previously have died and been excluded from the
LOS analysis in the pre-FDX period now surviving but requir-
ing extended care.
Mortality rates (28-day all-cause) following primary epi-
sodes of CDI were reduced to the lowest levels in hospitals A
and B, where FDX was used first line in all patients, although
there was also a statistically significant reduction in hospital
D, where FDX was only used first line for CDI recurrences.
Readmission within 30 days of the primary or recurrent
episode was not consistently affected by the introduction of
FDX. Only hospital A, where FDX was introduced for all
episodes of CDI, observed a statistically significant reduction
in the 30-day readmission rate following primary CDI epi-
sodes, although a contributor to this could be the relatively
long average LOS among the patients with CDI at this hospi-
tal, which may mitigate against readmission. Nevertheless,
this reduction is consistent with the significant reduction in
the recurrence rate (readmission data were not available for
hospital B, which also demonstrated a substantial difference in
recurrence).
Limitations
Some limitations of this series of service evaluations have been
described already in the discussion of each outcomemeasure. In
addition, the differing retest policies of hospitals affected our
ability to quantify the recurrence rate consistently across all the
evaluations, by positive toxin test result, i.e. different definitions
of ‘recurrence’ were used between hospitals and, so, the abso-
lute recurrence rates should not be compared between hospitals.
However, definitions of recurrence were consistent over time at
each hospital, so the pre-FDX vs. post-FDX comparisons for
each hospital are valid. The time to recurrence according to
toxin result was affected by each hospital’s retest policy; no
toxin-positive recurrence could occur within 14 (or 28) days
of primary CDI in the hospitals with this policy; hence, this
cannot be compared between hospitals. The time to recurrence
analysis was also affected by widespread missing dates of re-
currence. The definition of resolution of symptomswas not well
defined and prone to great variation between hospitals. In the
hospitals where toxin positivity was required for the diagnosis
of a recurrence, the LOS associated with primary CDI could be
an over-estimate due to their criteria for the diagnosis of recur-
rence. Some hospitals did not collect, or not consistently, data
on readmissions. This, again, limited us to comparing between
pre- and post-FDX introductionwithin each hospital, rather than
comparing outcomes between hospitals. In hospital C, the se-
lection of a sample of patients for collection of the full study
dataset introduces the possibility of bias compared to the other
hospitals where all episodes of CDI were included. However,
random sampling should have minimised this risk.
Conclusion
Although not designed as a formal comparison between hos-
pitals, the results of these service evaluations suggest that the
pattern of adoption of fidaxomicin (FDX) may affect the over-
all outcomes ofClostridium difficile infection (CDI) treatment
Fig. 2 Clostridium difficile infection (CDI) recurrence rates in the pre- and post-FDX observation periods at participating hospitals
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achieved by a hospital. In practice, the benefits of the superior
effect of FDX on the recurrence rate and 28-daymortality may
be realised to the greatest extent where FDX is used as the
routine first-line option for the treatment of CDI rather than in
selected patients only. A policy of selective use of FDX only
for recurrences had good outcomes in one hospital but was
based on a small number of treated cases and requires a larger
sample size for confirmation.
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